Skip to main content

MDGL

Stock
Health Care
Biotechnology

Performance overview

MDGL Price
Price Chart

Forward-looking statistics

Beta
1.24
Risk
65.12%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

madrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.

Company info

SectorHealth Care
IndustryBiotechnology
Employees234
Market cap$5.2B

Fundamentals

Enterprise value$6.0B
Revenue$317.4M
Revenue per employee
Profit margin-123.38%
Debt to equity16.85

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$17.84
Dividend per share
Revenue per share$14.56
Avg trading volume (30 day)$97M
Avg trading volume (10 day)$96M
Put-call ratio

Macro factor sensitivity

Growth+10.4
Credit+0.8
Liquidity-5.5
Inflation+8.0
Commodities+3.6
Interest Rates-1.0

Valuation

Dividend yield0.00%
PEG Ratio-21.41
Price to sales20.91
P/E Ratio-21.41
Enterprise Value to Revenue18.89
Price to book9.33

Upcoming events

Next earnings dayMay 1, 2025
Next dividend day
Ex. dividend day

News

Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates

Madrigal (MDGL) came out with a quarterly loss of $3.32 per share versus the Zacks Consensus Estimate of a loss of $3.62. This compares to loss of $7.38 per share a year ago.

Zacks Investment Research (May 1, 2025)
Madrigal CEO on Q4 earnings beat, MASH drug market opportunity

Bill Sibold, Madrigal Pharmaceuticals CEO , joins 'Fast Money' to talk quarterly results.

CNBC Television (February 26, 2025)
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis

On Wednesday, Madrigal Pharmaceuticals, Inc. MDGL reported two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra (resmetirom).

Benzinga (February 26, 2025)
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will take Accolade private.

CNBC (January 8, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free